Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selicrelumab + atezolizumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Selicrelumab + atezolizumab is an investigational combination therapy of two monoclonal antibodies for cancer immunotherapy. **Selicrelumab** is an agonistic IgG2 monoclonal antibody that targets CD40 on antigen-presenting cells (APCs), activating immune responses and priming CD8+ T cells. **Atezolizumab** is a humanized IgG1 monoclonal antibody targeting programmed cell death ligand 1 (PD-L1), blocking its interaction with PD-1 and B7-1 (CD80) and thus releasing the inhibition of tumor-specific cytotoxic T cell activity. The combination aims to synergistically boost anti-tumor immune responses in patients with advanced or metastatic solid tumors not amenable to standard treatment[1][3][4].
- Other names
- CD40 agonist + anti-PD-L1 antibodyselicrelumab + Tecentriq
02
Targets
CD40 (Cluster of differentiation 40 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on selicrelumab + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selicrelumab + atezolizumab.